A water-extract of the Korean traditional formulation Geiji-Bokryung-Hwan reduces atherosclerosis and hypercholesteremia in cholesterol-fed rabbits

Int Immunopharmacol. 2003 May;3(5):723-34. doi: 10.1016/S1567-5769(03)00073-0.

Abstract

Geiji-Bokryung-Hwan (GBH), a drug preparation consisting of five herbs of Cinnamomi Ramulus (Geiji), Poria Cocos (Bokryun), Mountan Cortex Radicis (Mokdanpi), Paeoniae Radix (Jakyak) and Persicae Semen (Doin), is a traditional Korean herbal medicine that is widely used in the treatment of atherosclerosis-related disorders. A water extract of GBH was found to scavenge 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals and inhibit low-density lipoprotein (LDL) oxidation more effectively than probucol, a well-known commercially available antioxidant. In order to evaluate the anti-atherogenic potential of this medication, New Zealand White (NZW) rabbits were fed a normal diet for 12 weeks, a high cholesterol diet, a high cholesterol diet containing 1% probucol or a high cholesterol diet containing 5% water-soluble extract of GBH. Both GBH and probucol reduced plasma cholesterol levels. LDLs from the GBH-treated group were more resistant to Cu(2+)-induced oxidation and contained more vitamin E than LDLs from the high cholesterol diet group. Endothelial damage, determined at week 6, was reduced by 55% in the GBH group (P<0.01). GBH treatment reduced an atherosclerotic area in the abdominal aorta by 58% (P<0.05) and cholesterol deposition in the thoracic aorta by 55% (P<0.05). The severity of atherosclerosis in the GBH group was significantly reduced after an adjustment using cholesterol exposure as an index of the cholesterol-lowering effect. On the other hand, diet-induced hyperlipidemic rabbits were given water extract of GBH in doses of 50 (Group B) and 200 mg/kg (Group C) and compared with controls (Group A). At 40 days after intervention in groups A, B and C, total and LDL cholesterol levels were significantly lowered (P<0.01). LDL/high density lipoprotein (HDL) ratio was also significantly decreased (P<0.01). This study concludes that the reduction in atherosclerosis by GBH relies not only on its cholesterol-lowering effect but also more heavily on its antioxidant potential, which prevents endothelial damage and inhibits LDL oxidative modification in hypercholesterolemic animals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / therapeutic use*
  • Arteriosclerosis / blood
  • Arteriosclerosis / drug therapy*
  • Arteriosclerosis / pathology
  • Biphenyl Compounds
  • Cholesterol, Dietary*
  • Cholesterol, LDL / blood
  • Endothelium, Vascular / pathology
  • Free Radical Scavengers / pharmacology
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / pathology
  • Lipoproteins / metabolism
  • Male
  • Oxidation-Reduction
  • Phytotherapy*
  • Picrates / metabolism
  • Plant Extracts / therapeutic use*
  • Rabbits
  • Vitamin E / metabolism

Substances

  • Anticholesteremic Agents
  • Biphenyl Compounds
  • Cholesterol, Dietary
  • Cholesterol, LDL
  • Free Radical Scavengers
  • Geiji-Bokryung-Hwan
  • Lipoproteins
  • Picrates
  • Plant Extracts
  • Vitamin E
  • 1,1-diphenyl-2-picrylhydrazyl